Phase separation of FSP1 promotes ferroptosis

Ferroptosis is evolving as a highly promising approach to combat difficult-to-treat tumour entities including therapy-refractory and dedifferentiating cancers1–3. Recently, ferroptosis suppressor protein-1 (FSP1), along with extramitochondrial ubiquinone or exogenous vitamin K and NAD(P)H/H+ as an electron donor, has been identified as the second ferroptosis-suppressing system, which efficiently prevents lipid peroxidation independently of the cyst(e)ine–glutathione (GSH)–glutathione peroxidase 4 (GPX4) axis4–6. To develop FSP1 inhibitors as next-generation therapeutic ferroptosis inducers, here we performed a small molecule library screen and identified the compound class of 3-phenylquinazolinones (represented by icFSP1) as potent FSP1 inhibitors. We show that icFSP1, unlike iFSP1, the first described on-target FSP1 inhibitor5, does not competitively inhibit FSP1 enzyme activity, but instead triggers subcellular relocalization of FSP1 from the membrane and FSP1 condensation before ferroptosis induction, in synergism with GPX4 inhibition. icFSP1-induced FSP1 condensates show droplet-like properties consistent with phase separation, an emerging and widespread mechanism to modulate biological activity7. N-terminal myristoylation, distinct amino acid residues and intrinsically disordered, low-complexity regions in FSP1 were identified to be essential for FSP1-dependent phase separation in cells and in vitro. We further demonstrate that icFSP1 impairs tumour growth and induces FSP1 condensates in tumours in vivo. Hence, our results suggest that icFSP1 exhibits a unique mechanism of action and synergizes with ferroptosis-inducing agents to potentiate the ferroptotic cell death response, thus providing a rationale for targeting FSP1-dependent phase separation as an efficient anti-cancer therapy.


Reporting Summary
Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: -Accession codes, unique identifiers, or web links for publicly available datasets -A description of any restrictions on data availability -For clinical datasets or third party data, please ensure that the statement adheres to our policy All data are available in the Article and the Supplementary Information, and from the corresponding author on reasonable request. Gel source images are shown in nature portfolio | reporting summary April 2023 Supplementary Fig. 2. All source data are provided in this paper. Cancer cell line data were mined from https://depmap.org/portal/. The prediction for phase separation of FSP1 was conducted by https://iupred2a.elte.hu and https://mobidb.bio.unipd.it.

Research involving human participants, their data, or biological material
Policy information about studies with human participants or human data. See also policy information about sex, gender (identity/presentation), and sexual orientation and race, ethnicity and racism. Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design
All studies must disclose on these points even when the disclosure is negative.

Sample size
For in vitro experiments, sample sizes were determined based on previous similar studies that have given statistically significant results (PMID: 31634899, 35922516). The number of animals studied per treatment group was determined based on our preliminary data and previous similar studies that have given statistically significant results (PMID: 35922516 and 25402683), and respects the limited use of animal models in line with the 3R recommendations: Replacement, Reduction, Refinement.
Data exclusions No data exclusions.

Replication
The experimental findings were reproduced as validated by at least three independent experiment in Fig 1c- Randomization For animal studies, mice were randomized into separate cages. For in vitro studies, randomization is not relevant since cells come in millions of populations and are automatically randomized and seeded to different wells for treatment.

Blinding
For animal study, mice were given a number prior to data collection and analysis. Data was collected and analyzed blindly. For in vitro experiments, investigators were not blinded, as standard in this manner of study, which contained multiple steps requiring distinct operations for accuracy and precision precluding blinding to experimental variables.

Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Authentication
None of the cell lines used were authenticated.

Mycoplasma contamination
All cell lines were tested negative for mycoplasma contamination.
Commonly misidentified lines (See ICLAC register) No commonly misidentified cell lines were used.

Animals and other research organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in Research Laboratory animals Five to six-weeks-old female C57BL6/J and athymic nude mice were obtained from Charles River and six to seven weeks-old mice were used for experiments. All mice were kept under standard conditions with water and food ad libitum and in a controlled environment (22 ± 2°C, 55 ± 5% humidity, 12 h light/dark cycle) in Helmholtz Munich animal facility under SPF-IVC standard conditions.

nature portfolio | reporting summary
April 2023

Wild animals
The study did not involve wild animals.

Reporting on sex
Experiments were performed on only female mice.
Field-collected samples The study did not involve field-collected samples.

Ethics oversight
All experiments were performed in compliance with the German Animal Welfare Law and have been approved by the institutional committee on animal experimentation and the government of Upper Bavaria (ROB-55.2-2532.Vet_02-17-167).
Note that full information on the approval of the study protocol must also be provided in the manuscript.

Flow Cytometry
Plots Confirm that: The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.

Methodology
Sample preparation 100,000 cells per well were seeded on a 12-well plate one day prior to the experiments. On the next day, cells were treated with 2.5 μM icFSP1 for 3 h, and then incubated with 1.5 μM C11-BODIPY 581/591 (Invitrogen, Cat#D3861) for 30 min in a 5% CO2 atmosphere at 37°C. Subsequently, cells were washed by PBS once and trypsinized, and then resuspended in 500 μL PBS. Cells were passed through a 40 m cell strainer and analyzed by a flow cytometer (CytoFLEX, Beckman Coulter) with a 488nm laser for excitation. Data was collected from the FITC detector (for the oxidized form of BODIPY) with a 525/40nm bandpass filter and from the PE detector (for the reduced form of BODIPY) with a 585/42 nm bandpass filter.

Instrument
CytoFLEX (Beckman Coulter) Software CytExpert v2.4 was used for data collection. FlowJo v10 was used for data analysis.

Cell population abundance
At least 10,000 cells were analyzed for each sample.

Gating strategy
Cell populations were separated from cellular debris using FSC and SSC.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.